Compare Hinge Health Inc. Class A Common Stock (HNGE) vs MaxLinear Inc. Common Stock (MXL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hinge Health Inc. Class A Common Stock vs MaxLinear Inc. Common Stock — how do they compare? Hinge Health Inc. Class A Common Stock trades at $103.99 (market cap $8.47B), while MaxLinear Inc. Common Stock trades at $75.3 (market cap $7.14B). The key difference: Hinge Health Inc. Class A Common Stock is the larger of the two by market cap, and Hinge Health Inc. Class A Common Stock is trading nearer its 52-week high, MaxLinear Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Hinge Health Inc. Class A Common Stock for 0 Days and MaxLinear Inc. Common Stock for 3 Days on average.
| HNGE | MXL | |
|---|---|---|
Market Cap | $8.47B | $7.14B |
Volume | 1,624,526 | 3,085,196 |
Sector | Health | Technology |
52-Week High | $105.14 | $128.03 |
52-Week Low | $31.17 | $13.05 |
Typical Hold Time | 0 Days | 3 Days |
Enterprise Value | $8.09B | $7.23B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hinge Health (HNGE) trades at $105.14, up 0.31% on the day and near its 52-week high. The stock shows strong analyst support with a 93.75% buy rating, though the current price exceeds the consensus target of $101.62. Recent earnings beat expectations in two of the last three quarters, with Q3 2026 results due November 2. Fundamentals indicate robust revenue growth projections from $588 million in 2025 to $720 million in 2026, alongside a shift to profitability, but valuation multiples like EV/EBITDA at 82.33 remain elevated.
The outlook is cautiously optimistic given projected profitability and expansion into migraine and GI care, but risks include high insider selling, competitive pressures, and the stock's premium valuation. Execution on growth targets and Q3 earnings will be critical for sustaining momentum.
MaxLinear (MXL) trades at $88.64, down 0.39% on the day, with strong technical momentum indicated by bullish moving averages and key support at $87. The company shows impressive revenue growth with Q2 2026 EPS beating expectations at $0.35 versus $0.33, though profitability remains challenged with a -18.24% net income margin. Recent AI-focused product launches like Topaz™ PON chips and strong infrastructure demand position MXL for continued growth.
MXL presents a compelling growth story driven by AI infrastructure demand, with analyst consensus at Buy (64.7%) and $91.67 price target offering 3.4% upside. However, negative profitability metrics and cash flow concerns require careful monitoring. The stock's 50.7% September surge (Motley Fool, Oct 2) reflects optimism, but execution risks and valuation premium warrant cautious optimism for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Hinge Health Inc. Class A Common Stock
Hinge Health Inc. operates a digital musculoskeletal (MSK) care platform that delivers exercise therapy for joint and muscle conditions through health plans and employers. Its Precision Motion Technology combines wearable sensors and computer vision to guide patients through clinician-directed physical therapy remotely.
Read more on HNGE →About MaxLinear Inc. Common Stock
MaxLinear develops analog and mixed-signal semiconductors for connectivity, communications, industrial, and data center applications.
Read more on MXL →
